Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olumacostat glasaretil - Dermira

Drug Profile

Olumacostat glasaretil - Dermira

Alternative Names: DRM 01; DRM-01B; VAL-001

Latest Information Update: 13 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QLT
  • Developer Dermira
  • Class Antiacnes; Furans; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne vulgaris

Most Recent Events

  • 08 Jun 2018 Discontinued - Phase-II for Acne vulgaris in Canada (Topical)
  • 08 Jun 2018 Discontinued - Phase-III for Acne vulgaris (In adolescents, In children, In the elderly, In adults) in Australia, Canada, USA (Topical)
  • 27 Apr 2018 Dermira completes a long term phase III safety trial in Acne vulgaris in USA, Australia and Canada (Topical, Gel) (NCT03127956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top